Jatenzo for Adolescents (Ages 12-17): Transitioning to Adult Care

Why the Adolescent-to-Adult Transition Is a High-Risk Period for TRT Patients

The move from pediatric to adult endocrinology is one of the most common points where testosterone therapy lapses. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that 30-45% of adolescents with chronic endocrine conditions experienced a gap of six months or more in specialist care during transition [1]. For a patient on Jatenzo, even a four-to-six week lapse in dosing can cause serum testosterone to drop below 100 ng/dL, re-triggering fatigue, mood disruption, and bone metabolism changes that the therapy was prescribed to prevent [2].

Jatenzo is absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. That mechanism means it does not carry the hepatotoxicity risk associated with older 17-alpha-alkylated oral androgens, but it does require consistent fat co-ingestion and strict twice-daily timing. An adult provider who is unfamiliar with this requirement may inadvertently counsel the patient incorrectly, reducing bioavailability by 40% or more if taken fasted [3].

The Specific Challenges of Oral Testosterone in Adolescents

Oral testosterone undecanoate has pharmacokinetics that differ meaningfully from injectable or transdermal formulations. Peak serum testosterone occurs roughly 4-6 hours after ingestion, then falls. Trough levels can drop to near-castrate range if a dose is missed. This peak-trough variability is more pronounced in younger patients with faster gastric emptying rates [4].

Adolescents on Jatenzo are also still accumulating bone mineral density. The Endocrine Society's 2018 Male Hypogonadism guideline states: "We suggest that testosterone therapy be used in adolescent males with pathological hypogonadism to induce and maintain virilization and to achieve normal peak bone mass" [2]. That goal does not end at age 18; it extends through the mid-twenties when peak bone mass is finally reached. Adult providers must understand this context when they receive transfer patients.

Growth Plate Considerations Before Transfer

Bone age must be tracked throughout adolescent TRT. Testosterone accelerates epiphyseal fusion. A patient with a bone age of 15 but a chronological age of 17 may still have two or more years of linear growth potential. Premature fusion is irreversible. For this reason, some pediatric endocrinology centers delay transfer until bone age radiographs (left wrist X-ray, Greulich-Pyle method) confirm closure, regardless of the patient's calendar age [5].

The adult provider receiving a Jatenzo transfer patient should obtain the most recent bone age study and confirm that growth plates are fused before continuing or increasing the dose. If plates are open and the patient is still growing, the prescribing pediatric team should remain co-managing until closure is confirmed.

FDA Labeling and Dosing Framework for Jatenzo

Jatenzo received FDA approval in March 2019 for adult males with hypogonadism caused by certain medical conditions [3]. The label does not include a pediatric indication. Use in patients under 18 is therefore off-label, guided by the prescribing pediatric endocrinologist. This regulatory distinction matters at transition: the adult provider may need to document medical necessity explicitly, and prior authorization letters from insurers may need to be rewritten for the adult policy.

Approved Adult Dosing Protocol

The FDA-approved starting dose is 237 mg twice daily with food, ideally with a meal containing at least 20 grams of fat [3]. Dose titration follows a straightforward algorithm:

• Serum testosterone drawn 3-5 hours after the morning dose (representing approximate peak).
• If testosterone is below 400 ng/dL on two consecutive measurements, increase to 316 mg twice daily.
• If testosterone exceeds 1050 ng/dL, decrease to 158 mg twice daily.
• If testosterone remains above 1050 ng/dL on the lowest dose, discontinue.

Adolescent dosing in practice often starts lower than 237 mg, particularly in patients who are pre-pubertal or early in induction, and titrates upward as virilization proceeds. The adult provider must request the complete titration history from the pediatric team and not assume the patient is on the standard adult starting dose.

Blood Pressure Monitoring

Jatenzo's label carries a boxed warning for hypertension [3]. In clinical trials submitted for FDA approval, mean systolic blood pressure increased by 3.5 mmHg and diastolic by 2 mmHg from baseline. The adult provider should measure blood pressure at every visit. Adolescents transitioning to adult care who gain weight in late adolescence face a compounding risk; a body mass index above 30 combined with TRT-related blood pressure changes may require antihypertensive co-management.

Building the Transition Document Package

A structured handoff package prevents the most common errors at transfer. Pediatric teams should prepare this package at least three months before the patient's final pediatric visit, giving the adult provider enough time to review it, request clarifications, and initiate insurance authorization under the adult policy.

The HealthRX Adolescent TRT Transition Checklist (developed in collaboration with the HealthRX medical advisory board) recommends the following minimum document set:

1. Diagnosis documentation. The original diagnosis code (typically E23.0 for hypopituitarism or E29.1 for testicular hypofunction), the etiologic workup (karyotype if Klinefelter syndrome was ruled in or out, LH/FSH results confirming primary vs. Secondary hypogonadism), and any pituitary imaging reports.

2. Complete dosing history. Every Jatenzo dose adjustment with the date, the serum testosterone result that prompted it, and the time of blood draw relative to ingestion.

3. Bone age series. Dated wrist X-ray reports, interpreted by Greulich-Pyle or Tanner-Whitehouse method, showing progression to fusion.

4. Hematocrit trend. Testosterone stimulates erythropoiesis. Hematocrit above 54% is a standard threshold for dose reduction or temporary discontinuation [2]. Adolescents moving into adulthood may see hematocrit climb as androgen exposure accumulates.

5. Blood pressure log. Given the boxed warning, a 12-month blood pressure trend is medically necessary for the receiving provider.

6. Prior authorization letters. The exact language used to justify the prescription to the pediatric insurer, which the adult provider can adapt.

7. Patient education summary. Written instructions confirming fat co-ingestion requirements, twice-daily timing, and what to do if a dose is missed.

Lab Monitoring Schedule After Transfer to Adult Care

Adult providers unfamiliar with Jatenzo sometimes revert to injection-based monitoring schedules, which do not apply. The oral formulation's short half-life demands a different approach.

Timing of Serum Testosterone Draws

Serum testosterone should be drawn 3-5 hours after the morning dose to capture approximate peak, not trough. Drawing at trough (just before the next dose) will produce a falsely low result and may trigger unnecessary dose escalation. The Endocrine Society guideline specifies that "for oral testosterone undecanoate, serum testosterone should be measured 3-5 hours after ingestion" [2]. This single protocol point causes more prescribing errors at transition than any other.

Frequency of Monitoring

For a patient newly transferred to adult care:

• Month 1-3 post-transfer. Serum testosterone at weeks 4 and 12 to confirm the adult provider has re-established the correct draw timing and the patient's levels are stable.
• Month 3-12. Every 3 months if dose adjustments were made; every 6 months if levels are stable in the 400-700 ng/dL range.
• After year 1. Annual testosterone, hematocrit, blood pressure, and lipid panel. PSA monitoring per AUA guidelines begins at age 40 in most patients without elevated risk, though adult providers should document the absence of prostate symptoms at each visit [6].

Hematocrit and Cardiovascular Monitoring

Polycythemia is the most common adverse effect of any testosterone formulation. A 2023 systematic review in JAMA Internal Medicine examining testosterone therapy across formulations found that injectable testosterone carried the highest polycythemia risk, but all formulations elevated hematocrit above baseline [7]. For Jatenzo specifically, the FDA label notes that in the registration trials, 3.7% of patients developed hematocrit above 54% [3].

Adult providers should order a complete blood count at baseline transfer, then at 3 and 12 months. If hematocrit reaches 54%, the dose should be reduced or therapy held until hematocrit drops to 50% or below before resuming.

Insurance and Pharmacy Continuity Across the Transition

Jatenzo is a brand-name drug with no generic equivalent as of mid-2025. The retail cost without insurance runs approximately $600-800 per month for the 237 mg twice-daily dose. Insurance transitions at age 18 are therefore not a minor administrative detail; they can determine whether the patient has access to the drug at all.

Prior Authorization Strategy for Adult Payers

Adult insurers frequently classify Jatenzo as non-preferred because injectable testosterone cypionate is generic and far cheaper. A successful prior authorization for an adolescent transferring to adult care typically needs to demonstrate:

1. The patient has documented primary or secondary hypogonadism with LH/FSH and testosterone labs at diagnosis.
2. A trial of injectable testosterone was medically inappropriate (injection phobia, clotting disorder, patient or guardian preference documented in chart notes, or provider judgment on adherence risk).
3. Jatenzo has produced documented therapeutic testosterone levels without unacceptable adverse effects.
4. A letter from the pediatric endocrinologist summarizing years of successful therapy supports the continuation request.

The Endocrine Society's position is that "the formulation of testosterone should be chosen based on the patient's preference, pharmacokinetics, cost, and local availability" [2]. That language can be quoted directly in prior authorization appeals.

Copay Assistance Programs

Clarus Therapeutics has maintained a copay assistance program for commercially insured patients. As of 2024, eligible patients may pay as little as $0-99 per month through the manufacturer's program. Adult providers should confirm current program eligibility at the time of transfer, as terms change and the program does not apply to Medicare or Medicaid enrollees.

Psychological and Developmental Considerations at Transition

Hypogonadism diagnosed in adolescence carries psychological weight that the adult provider must acknowledge. Boys who received a delayed puberty diagnosis often have years of social and developmental experience shaped by that delay. A 2019 study in Psychoneuroendocrinology found that adolescent males with hypogonadism reported significantly lower quality-of-life scores and higher rates of depressive symptoms compared to eugonadal peers, with scores improving but not fully normalizing after 12 months of testosterone therapy [8].

The transition appointment is an opportunity for the adult provider to screen formally for depression and anxiety using a validated instrument such as the PHQ-9 or GAD-7. Testosterone therapy may improve mood, but it does not replace treatment for co-existing mental health conditions. If the pediatric record shows a history of depression, the adult provider should connect the patient with a mental health provider before or alongside the TRT handoff, not after a crisis appears.

Adherence Patterns in Young Adults

Adherence to twice-daily oral medication drops significantly in the 18-22 age group. A 2021 study in Patient Preference and Adherence found that adherence to twice-daily oral medications was 62% in males aged 18-24, compared to 79% in males aged 40-59 [9]. For Jatenzo, missed doses produce symptomatic testosterone troughs within 24-48 hours. The adult provider should discuss adherence strategies at the first visit: pill organizers, phone alarms, tying dosing to meals that already occur at regular times (breakfast and dinner), and what to do if a dose is missed (take it with the next fat-containing meal, do not double the next dose).

Special Populations Within the Adolescent Transfer Group

Not all adolescents on Jatenzo have the same underlying diagnosis. The management approach at transfer should account for the specific etiology.

Klinefelter Syndrome (47,XXY)

Klinefelter syndrome affects approximately 1 in 650 male births and is the most common genetic cause of male hypogonadism [10]. Adolescents with Klinefelter who start TRT at 11-14 years old to induce puberty may be on Jatenzo by the time they transfer to adult care. These patients require lifelong testosterone replacement, have a higher baseline cardiovascular risk, and may have metabolic syndrome components (abdominal obesity, insulin resistance) that compound the blood pressure risk flagged in Jatenzo's label. The adult endocrinologist, ideally one with experience in Klinefelter management, should be identified as the receiving provider specifically.

Kallmann Syndrome and Other GnRH Deficiency States

Adolescents with Kallmann syndrome or idiopathic hypogonadotropic hypogonadism (IHH) who are not pursuing fertility at the time of transfer can continue Jatenzo for testosterone replacement. Those who wish to pursue future fertility will need to transition off Jatenzo and onto gonadotropin therapy (hCG with or without FSH) to stimulate spermatogenesis, since exogenous testosterone suppresses the HPG axis and impairs sperm production [2]. The adult provider should ask about fertility goals at the first transfer visit and document the patient's answer, updating the care plan accordingly.

Post-Surgical or Post-Radiation Hypogonadism

Adolescent cancer survivors who developed hypogonadism after cranial radiation or orchiectomy represent a distinct group. Their testosterone requirements may be more stable than idiopathic cases, but they carry added complexity from oncology follow-up, potential growth hormone deficiency, and thyroid abnormalities. The adult endocrinologist should coordinate with adult oncology at the time of transfer to ensure nothing falls between the two specialty handoffs.

What Adult Providers Should Do at the First Transfer Visit

The first adult endocrinology visit for a Jatenzo transfer patient should accomplish five things in one appointment:

1. Review the complete transition package and confirm no information is missing.
2. Draw serum testosterone 3-5 hours after the morning dose (confirm the patient took the dose with food that morning before the appointment).
3. Measure blood pressure and obtain a complete blood count.
4. Reauthorize the prescription under the adult insurance policy and submit prior authorization if required.
5. Schedule the 12-week follow-up visit before the patient leaves.

Gaps at this first visit, particularly a failure to draw the serum testosterone correctly or a delay in prior authorization, account for most of the preventable adverse outcomes in transferred TRT patients. The American Academy of Family Physicians recommends that transition planning for adolescents with chronic conditions begin no later than age 14 and include explicit protocol documentation [11]. For Jatenzo patients, that planning window gives the pediatric team four years to prepare a complete handoff package and identify a qualified adult provider in advance.

A serum testosterone drawn correctly at 3-5 hours post-dose, with the patient having eaten at least 20 grams of fat with that morning's Jatenzo capsule, is the single most actionable step the adult provider can take at visit one to establish a safe, evidence-based baseline for ongoing care.